Global Head and Neck Cancer Therapeutics Market, By Type (Diagnostic Methods {Biopsy, Imaging, Endoscopy, Others} v/s Treatment Type {Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy}), By Treatment Type (By Disease Indication {Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer}, By Route of Administration {Injectable, Oral}, By Therapeutic Class {PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors}), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Company, Opportunities and Forecast, 2027
Global head and neck cancer therapeutics market value in 2021 was USD2024.33 million, which is expected to grow further with a CAGR of 7.22% during the forecast period, 2023-2027, to achieve the market value of USD3126.26 million by 2027F. This impressive growth of the market can be attributed to the advancing healthcare industry, majorly the therapeutics sector for cancer treatments. Increasing instances of cancer like head cancer, throat cancer further drive the growth of the global head and neck cancer therapeutics market in the upcoming five years. Additionally, the market is also bound to experience growth due to advancements in the pharmaceutical industry. Precision medicine is highly implemented when cancer therapeutics are involved. The popularity of precision medicine, along with its specificity toward the cancer treatment of the respective patient being based on the type of cancer along with genetic information from the patient, enhances the success rates of the procedure, therefore, supporting the growth of the global head and neck cancer therapeutics market in the next five years. Increased consumption of tobacco and tobacco-based products, rapidly increasing smoking habits, and alcohol consumption among the population is also contributing to the increasing cases of throat cancer, which leads to the growth of the global head and neck cancer therapeutics market in the future five years.
The global head and neck cancer therapeutics market is majorly segmented by type, end user, regional distribution, and competition. By type, the market is differentiated into diagnostic methods and treatment type, where segments of the treatment type market are further analyzed by disease indication, route of administration, and therapeutic class. Diagnostic methods are forecast to dominate the market by holding the largest revenue shares of the market in the upcoming five years due to increasing demand for the early and efficient diagnosis of patients suffering from cancer. Treatment for the early stages of cancer is rather feasible and has a higher success rate; therefore, the demand for diagnosing cancer at its early stage drives the growth of the segment along with the growth of the global head and neck cancer therapeutics market in the next five years.
Treatment type segment is forecast to advance in the next five years and account for a share of over 41% in 2027 on the grounds of increasing advancement in the pharmaceutical and therapeutic sector. Surging demand for effective treatment for growing instances of cancer further aids the market growth.
Major companies in the global head and neck cancer therapeutics market are Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc., among others.
Years considered for this report:
Historical Years: 2017- 2020
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2023 – 2027
Objective of the Study:
- To analyze the market size of global head and neck cancer therapeutics market from 2017 to 2020.
- To estimate and forecast the market size of global head and neck cancer therapeutics market from 2021 to 2022 and growth rate until 2027.
- To classify and forecast global head and neck cancer therapeutics market based on type, end user, regional distribution, and competitional landscape.
- To identify dominant region or segment in the global head and neck cancer therapeutics market.
- To identify drivers and challenges for global head and neck cancer therapeutics market.
- To examine competitive developments such as expansions, new product & service launches, mergers & acquisitions, etc., in global head and neck cancer therapeutics market.
- To identify and analyze the profile of leading players operating in global head and neck cancer therapeutics market.
- To identify key sustainable strategies adopted by market players in global head and neck cancer therapeutics market.
TechSci Research calculated the market size of global head and neck cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products & services and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
- Manufacturers & service providers, suppliers
- Distributors and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to head and neck cancer therapeutics
- Market research and consulting firms
Report Scope:
In this report, global head and neck cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Head and Neck Cancer Therapeutics Market, By Type:
- Diagnostic Methods
- Biopsy
- Imaging
- Endoscopy
- Others
- Treatment Type
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Head and Neck Cancer Therapeutics Market, By Treatment Type, By Disease Indication:
- Lip and Oral Cavity Cancer
- Laryngeal Cancer
- Oropharyngeal Cancer
- Salivary Gland Cancer
- Nasopharyngeal Cancer
- Hypopharyngeal Cancer
- Head and Neck Cancer Therapeutics Market, By Treatment Type, By Route of Administration:
- Injectable
- Oral
- Head and Neck Cancer Therapeutics Market, By Treatment Type, By Therapeutic Class:
- PD Inhibitors
- EGFR Inhibitors
- Microtubule Inhibitors
- Head and Neck Cancer Therapeutics Market, By End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
- Head and Neck Cancer Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Singapore
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in global head and neck cancer therapeutics market.
Company Information
- Detailed analysis and profiling of additional market players (up to five).
- 1. Product Overview
- 2. Research Methodology
- 3. Executive Summary
- 4. Voice of Customer
- 4.1. Brand Awareness
- 4.2. Preferred Diagnostic Method
- 4.3. Preferred Treatment Type
- 4.4. Preferred Route of Administration
- 5. Global Head and Neck Cancer Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Diagnostic Methods v/s Treatment Type)
- 5.2.1.1. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
- 5.2.1.2. By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
- 5.2.1.2.1. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
- 5.2.1.2.2. By Route of Administration (Injectable, Oral)
- 5.2.1.2.3. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
- 5.2.1.3. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 5.2.2. By Region
- 5.2.3. By Company (2021)
- 5.3. Product Market Map
- 6. North America Head and Neck Cancer Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.1.1. By Diagnostic Methods
- 6.2.1.2. By Treatment Type
- 6.2.1.2.1. By Disease Indication
- 6.2.1.2.2. By Route of Administration
- 6.2.1.2.3. By Therapeutic Class
- 6.2.1.3. By End User
- 6.2.2. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Head and Neck Cancer Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.1.1. By Diagnostic Methods
- 6.3.1.2.1.2. By Treatment Type
- 6.3.1.2.1.2.1. By Disease Indication
- 6.3.1.2.1.2.2. By Route of Administration
- 6.3.1.2.1.2.3. By Therapeutic Class
- 6.3.1.2.2. By End User
- 6.3.2. Canada Head and Neck Cancer Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.1.1. By Diagnostic Methods
- 6.3.2.2.1.2. By Treatment Type
- 6.3.2.2.1.2.1. By Disease Indication
- 6.3.2.2.1.2.2. By Route of Administration
- 6.3.2.2.1.2.3. By Therapeutic Class
- 6.3.2.2.2. By End User
- 6.3.3. Mexico Head and Neck Cancer Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.1.1. By Diagnostic Methods
- 6.3.3.2.1.2. By Treatment Type
- 6.3.3.2.1.2.1. By Disease Indication
- 6.3.3.2.1.2.2. By Route of Administration
- 6.3.3.2.1.2.3. By Therapeutic Class
- 6.3.3.2.2. By End User
- 7. Europe Head and Neck Cancer Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.1.1. By Diagnostic Methods
- 7.2.1.2. By Treatment Type
- 7.2.1.2.1. By Disease Indication
- 7.2.1.2.2. By Route of Administration
- 7.2.1.2.3. By Therapeutic Class
- 7.2.1.3. By End User
- 7.2.2. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Head and Neck Cancer Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.1.1. By Diagnostic Methods
- 7.3.1.2.1.2. By Treatment Type
- 7.3.1.2.1.2.1. By Disease Indication
- 7.3.1.2.1.2.2. By Route of Administration
- 7.3.1.2.1.2.3. By Therapeutic Class
- 7.3.1.2.2. By End User
- 7.3.2. Germany Head and Neck Cancer Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.1.1. By Diagnostic Methods
- 7.3.2.2.1.2. By Treatment Type
- 7.3.2.2.1.2.1. By Disease Indication
- 7.3.2.2.1.2.2. By Route of Administration
- 7.3.2.2.1.2.3. By Therapeutic Class
- 7.3.2.2.2. By End User
- 7.3.3. United Kingdom Head and Neck Cancer Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.1.1. By Diagnostic Methods
- 7.3.3.2.1.2. By Treatment Type
- 7.3.3.2.1.2.1. By Disease Indication
- 7.3.3.2.1.2.2. By Route of Administration
- 7.3.3.2.1.2.3. By Therapeutic Class
- 7.3.3.2.2. By End User
- 7.3.4. Italy Head and Neck Cancer Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.1.1. By Diagnostic Methods
- 7.3.4.2.1.2. By Treatment Type
- 7.3.4.2.1.2.1. By Disease Indication
- 7.3.4.2.1.2.2. By Route of Administration
- 7.3.4.2.1.2.3. By Therapeutic Class
- 7.3.4.2.2. By End User
- 7.3.5. Spain Head and Neck Cancer Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.1.1. By Diagnostic Methods
- 7.3.5.2.1.2. By Treatment Type
- 7.3.5.2.1.2.1. By Disease Indication
- 7.3.5.2.1.2.2. By Route of Administration
- 7.3.5.2.1.2.3. By Therapeutic Class
- 7.3.5.2.2. By End User
- 8. Asia Pacific Head and Neck Cancer Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.1.1. By Diagnostic Methods
- 8.2.1.2. By Treatment Type
- 8.2.1.2.1. By Disease Indication
- 8.2.1.2.2. By Route of Administration
- 8.2.1.2.3. By Therapeutic Class
- 8.2.1.3. By End User
- 8.2.2. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Head and Neck Cancer Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.1.1. By Diagnostic Methods
- 8.3.1.2.1.2. By Treatment Type
- 8.3.1.2.1.2.1. By Disease Indication
- 8.3.1.2.1.2.2. By Route of Administration
- 8.3.1.2.1.2.3. By Therapeutic Class
- 8.3.1.2.2. By End User
- 8.3.2. India Head and Neck Cancer Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.1.1. By Diagnostic Methods
- 8.3.2.2.1.2. By Treatment Type
- 8.3.2.2.1.2.1. By Disease Indication
- 8.3.2.2.1.2.2. By Route of Administration
- 8.3.2.2.1.2.3. By Therapeutic Class
- 8.3.2.2.2. By End User
- 8.3.3. Japan Head and Neck Cancer Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.1.1. By Diagnostic Methods
- 8.3.3.2.1.2. By Treatment Type
- 8.3.3.2.1.2.1. By Disease Indication
- 8.3.3.2.1.2.2. By Route of Administration
- 8.3.3.2.1.2.3. By Therapeutic Class
- 8.3.3.2.2. By End User
- 8.3.4. Australia Head and Neck Cancer Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Type
- 8.3.4.2.1.1. By Diagnostic Methods
- 8.3.4.2.1.2. By Treatment Type
- 8.3.4.2.1.2.1. By Disease Indication
- 8.3.4.2.1.2.2. By Route of Administration
- 8.3.4.2.1.2.3. By Therapeutic Class
- 8.3.4.2.2. By End User
- 8.3.5. South Korea Head and Neck Cancer Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Type
- 8.3.5.2.1.1. By Diagnostic Methods
- 8.3.5.2.1.2. By Treatment Type
- 8.3.5.2.1.2.1. By Disease Indication
- 8.3.5.2.1.2.2. By Route of Administration
- 8.3.5.2.1.2.3. By Therapeutic Class
- 8.3.5.2.2. By End User
- 8.3.6. Singapore Head and Neck Cancer Therapeutics Market Outlook
- 8.3.6.1. Market Size & Forecast
- 8.3.6.1.1. By Value
- 8.3.6.2. Market Share & Forecast
- 8.3.6.2.1. By Type
- 8.3.6.2.1.1. By Diagnostic Methods
- 8.3.6.2.1.2. By Treatment Type
- 8.3.6.2.1.2.1. By Disease Indication
- 8.3.6.2.1.2.2. By Route of Administration
- 8.3.6.2.1.2.3. By Therapeutic Class
- 8.3.6.2.2. By End User
- 9. South America Head and Neck Cancer Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.1.1. By Diagnostic Methods
- 9.2.1.2. By Treatment Type
- 9.2.1.2.1. By Disease Indication
- 9.2.1.2.2. By Route of Administration
- 9.2.1.2.3. By Therapeutic Class
- 9.2.1.3. By End User
- 9.2.2. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Head and Neck Cancer Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.1.1. By Diagnostic Methods
- 9.3.1.2.1.2. By Treatment Type
- 9.3.1.2.1.2.1. By Disease Indication
- 9.3.1.2.1.2.2. By Route of Administration
- 9.3.1.2.1.2.3. By Therapeutic Class
- 9.3.1.2.2. By End User
- 9.3.2. Argentina Head and Neck Cancer Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.1.1. By Diagnostic Methods
- 9.3.2.2.1.2. By Treatment Type
- 9.3.2.2.1.2.1. By Disease Indication
- 9.3.2.2.1.2.2. By Route of Administration
- 9.3.2.2.1.2.3. By Therapeutic Class
- 9.3.2.2.2. By End User
- 9.3.3. Colombia Head and Neck Cancer Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.1.1. By Diagnostic Methods
- 9.3.3.2.1.2. By Treatment Type
- 9.3.3.2.1.2.1. By Disease Indication
- 9.3.3.2.1.2.2. By Route of Administration
- 9.3.3.2.1.2.3. By Therapeutic Class
- 9.3.3.2.2. By End User
- 10. Middle East and Africa Head and Neck Cancer Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.1.1. By Diagnostic Methods
- 10.2.1.2. By Treatment Type
- 10.2.1.2.1. By Disease Indication
- 10.2.1.2.2. By Route of Administration
- 10.2.1.2.3. By Therapeutic Class
- 10.2.1.3. By End User
- 10.2.2. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Head and Neck Cancer Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.1.1. By Diagnostic Methods
- 10.3.1.2.1.2. By Treatment Type
- 10.3.1.2.1.2.1. By Disease Indication
- 10.3.1.2.1.2.2. By Route of Administration
- 10.3.1.2.1.2.3. By Therapeutic Class
- 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Head and Neck Cancer Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.1.1. By Diagnostic Methods
- 10.3.2.2.1.2. By Treatment Type
- 10.3.2.2.1.2.1. By Disease Indication
- 10.3.2.2.1.2.2. By Route of Administration
- 10.3.2.2.1.2.3. By Therapeutic Class
- 10.3.2.2.2. By End User
- 10.3.3. UAE Head and Neck Cancer Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.1.1. By Diagnostic Methods
- 10.3.3.2.1.2. By Treatment Type
- 10.3.3.2.1.2.1. By Disease Indication
- 10.3.3.2.1.2.2. By Route of Administration
- 10.3.3.2.1.2.3. By Therapeutic Class
- 10.3.3.2.2. By End User
- 11. Clinical Trial Analysis
- 12. Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market
- 13. Market Dynamics
- 13.1. Drivers
- 13.2. Challenges
- 14. Market Trends & Developments
- 15. Competitive Landscape
- 15.1. Competition Outlook
- 15.2. Players Profiled
- 15.2.1. Eli Lilly and Company
- 15.2.2. Bristol Myers Squibb Company
- 15.2.3. Sanofi S.A.
- 15.2.4. Merck & Co., Inc.
- 15.2.5. Pfizer Inc
- 15.2.6. AbbVie Inc.
- 15.2.7. Bayer AG
- 15.2.8. F. Hoffmann-La Roche Ltd.
- 15.2.9. Fresenius Medical Care AG & Co. KGaA
- 15.2.10. Sun Pharmaceutical Industries Ltd.
- 15.2.11. Teva Pharmaceutical Industries Limited
- 15.2.12. AstraZeneca Plc.
- 15.2.13. Astellas Pharma Inc.
- 15.2.14. AB Science SA
- 15.2.15. Boston Biomedical, Inc.
- 16. Strategic Recommendations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook